Skip to main content
Fig. 2 | Cancer Imaging

Fig. 2

From: Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers

Fig. 2

Therapeutic monitoring of 18F-FDG-PET in 71-years old male with advanced pulmonary adenocarcinoma who received pembrolizumab monotherapy as 1st line treatment. a 18F-FDG-PET/CT before pembrolizumab initiation shows primary site in the right upper lobe and hilum-mediastinal lymphadenopathy. Mediastinal lymphadenopathy before trachea revealed increased accumulation of 18F-FDG (black and white arrows) with SUVmax of 15, corresponding to that on CT scan (red arrow). b At 1 month after pmebrolizumab treatment, uptake of 18F-FDG on PET was obviously decreased with SUVmax of 3, but the morphological size of its lymphadenopathy was not changing (red arrow). c At 3 months after its treatment, there was no accumulation of 18F-FDG in primary site and lymphadenopathy (black and white arrows) with morphological shrinkage on CT scan (red arrow)

Back to article page